摘要
目的探讨重组人生长激素（ｒｈＧＨ）对青春期前特发性生长激素缺乏症（ＩＧＨＤ）患者的疗效。方法对３家医院的６３例ＩＧＨＤ以ｒｈＧＨ进行治疗，每晚临睡前皮下注射０．１ＩＵ／ｋｇ共６个月。结果６３例患儿身高平均增加（７．０±１．６）厘米，年生长速度由治疗前的（２．９±０．９）厘米／年，增加到（１４．０±３．２）厘米／年，身高标准差计分（ＳＤＳ）由治疗前的（－４．８±１．７）变为（－３．９±１．６）；体重也明显增加，但对骨龄无明显促进作用。治疗期间有３９．７％的患儿出现亚临床甲状腺功能低减，２２．４％的患儿于注射局部曾出现短暂的红肿或痒等，７．９％的患儿出现血清ＡＬＴ轻度升高，但所有这些现象均未影响患儿体格的线性增长。结论ｒｈＧＨ是治疗ＩＧＨＤ的一种安全、有效的促生长药物。
Objective To assess the efficacy of recombinant human growth hormone (rhGH), produced by Shanghai Institute of Cell Biology, in idiopathic growth hormone deficient (IGHD) children before puberty. Methods This noncomparative multicentre prospective study included 63 children (7 girls and 56 boys) with IGHD, who were treated with daily sc injections of rhGH (0.1 IU/kg) before sleep for six months. Results The mean height, mean growth velocity and mean height SDS increased from (119.7±11.8)cm, (2.9±0.9)cm/year and -4.8±1.7 to (126.7±114.4)cm, (14.0±3.2)cm/year and -3.9±1.6, respectively (P<0.05). Atthesametime,the mean weight also increasedstrikingly, but no advanced bone maturation was noted. During the course of rhGHtherapy,therewere39.7%,22.4% and 7.9% patients suffering from subclinical hypothyroidism, local reactions in injection sites and slight increment of the serum ALT levels respectively. All of these phenomena had no effect of their linear body growth. Conclusion rhGH appears an effective and safe drug for promoting growth in IGHD.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
1999年第1期8-11,共4页
Chinese Journal of Endocrinology and Metabolism
关键词
生长激素缺乏症
重组人生长激素
激素疗法
Idiopathic growth hormone deficiency Recombinant human growth hormone
